List of Excipients in Branded Drug TWIRLA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Agile Therapeutics Inc	TWIRLA	levonorgestrel/ethinyl estradiol	71671-100	CAPRIC ACID
Agile Therapeutics Inc	TWIRLA	levonorgestrel/ethinyl estradiol	71671-100	COPOVIDONE K25-31
Agile Therapeutics Inc	TWIRLA	levonorgestrel/ethinyl estradiol	71671-100	CROSPOVIDONE

Twirla Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

Twirla is a once-weekly contraceptive transdermal system containing levonorgestrel and ethinyl estradiol. Its commercial opportunity depends less on adding new excipients than on improving adhesive performance, skin tolerability, wear reliability, manufacturing throughput, and product differentiation. The highest-value excipient opportunities are drug-in-adhesive optimization, moisture and heat resistance, reduced skin residue, and improved adhesion for users with higher body mass index.

What is Twirla and how does its formulation work?

Twirla is an extended-release transdermal contraceptive approved by the FDA in 2020. Each system delivers 120 mcg of levonorgestrel and 30 mcg of ethinyl estradiol per day for seven days. Users apply one patch weekly for three consecutive weeks, followed by one patch-free week.[1]

Twirla formulation and dosage form

Attribute	Twirla specification
Active ingredients	Levonorgestrel and ethinyl estradiol
Daily nominal delivery	120 mcg levonorgestrel and 30 mcg ethinyl estradiol
Administration	Transdermal
Dosing frequency	Once weekly
Treatment cycle	Three weekly patches followed by one patch-free week
Patch area	Approximately 28 cm²
Product type	Drug-in-adhesive transdermal system
FDA application	NDA 210186
Initial U.S. approval	May 22, 2020
Therapeutic category	Hormonal contraception

Twirla uses a multilayer patch structure consisting of a backing layer, drug-containing adhesive matrix, and release liner. The FDA-approved labeling identifies polyisobutylene and crospovidone among the inactive ingredients.[1] The adhesive matrix is central to both drug delivery and commercial performance because it controls skin contact, drug diffusion, patch wear, removal characteristics, and patient experience.

What excipients are used in Twirla?

The principal disclosed excipients are functional rather than merely formulation-supporting ingredients.

Polyisobutylene adhesive

Polyisobutylene provides pressure-sensitive adhesion and contributes to the drug-in-adhesive matrix. Its molecular weight distribution affects:

• Initial tack
• Seven-day adhesion
• Cold-flow behavior
• Skin residue
• Peel force
• Drug diffusion
• Processing viscosity
• Coating uniformity

A polyisobutylene system can offer strong adhesion without the sensitization profile associated with some acrylic or rosin-based systems. Its limitations can include residue, edge lifting, and sensitivity to temperature and skin oils.

Crospovidone as a matrix modifier

Crospovidone is commonly associated with disintegration in oral dosage forms, but it can also act as a functional excipient in a transdermal matrix. In Twirla, it may influence matrix structure, drug dispersion, mechanical properties, and release behavior.

For a transdermal patch, crospovidone can affect:

• Drug crystallization
• Matrix porosity
• Diffusion pathways
• Active-ingredient homogeneity
• Adhesive cohesion
• Long-term physical stability

Any change to crospovidone grade, particle size, moisture content, or supplier could alter the critical quality attributes of the patch.

Backing and release-liner materials

Backing and release-liner materials are not conventional excipients, but they influence product quality. Key variables include:

• Water-vapor transmission
• Flexibility
• Drug migration
• Adhesive anchoring
• Removal force
• Printability
• Packaging compatibility
• Protection from heat and humidity

A liner that removes cleanly without disturbing the adhesive matrix is commercially important. A backing layer that limits drug loss while remaining conformable can improve real-world wear.

Which excipient attributes create the largest commercial opportunities?

The strongest opportunities are linked to measurable user failures rather than new pharmacology.

Improving seven-day adhesion

Twirla’s principal usability requirement is sustained adhesion for seven days under normal bathing, exercise, sweating, and clothing friction. Adhesion failure can lead to replacement patches, missed dosing, customer complaints, and reduced persistence.

Excipient and material strategies include:

1. Optimizing polyisobutylene molecular weight and polymer blending.
2. Adding a compatible tackifier with acceptable extractables and leachables.
3. Adjusting adhesive coat weight.
4. Modifying matrix cohesion to reduce edge lift.
5. Using a moisture-tolerant adhesive architecture.
6. Improving compatibility between the drug matrix and backing film.

The commercial value is high because even modest reductions in patch detachment can improve patient retention and lower customer-support costs.

Reducing skin irritation

Hormonal patches are exposed to the skin for long periods, making irritation a major product-quality concern. Potential contributors include adhesive chemistry, occlusion, residual solvent, drug concentration gradients, and removal force.

Excipient strategies include:

• Lower-irritancy pressure-sensitive adhesives
• Reduced residual solvent
• Controlled moisture transmission
• Less aggressive tackifier systems
• Softer or more conformable matrix materials
• Lower peel-force release liners
• Adhesive designs that reduce occlusion

A reformulation that improves tolerability may support a line extension, a new patch size, or a lifecycle-management supplement. It would also require evidence that levonorgestrel and ethinyl estradiol delivery remains equivalent.

Reducing adhesive residue

Visible or tactile residue can negatively affect patient acceptance. It can also create a perception of poor product quality even when drug delivery is unaffected.

Commercially useful approaches include:

• Increasing cohesive strength without reducing skin adhesion
• Narrowing the adhesive molecular-weight distribution
• Reducing low-molecular-weight polymer fractions
• Selecting lower-residue tackifiers
• Improving the balance between adhesive wetting and clean removal
• Modifying the release liner to prevent matrix disturbance

Residue reduction is particularly valuable for a product intended for long-term, repeated use.

Improving performance across body mass index groups

The FDA label states that Twirla may be less effective in women with a body mass index of 30 kg/m² or greater and identifies this population as having an increased risk of venous thromboembolism.[1] The efficacy limitation creates a commercial constraint that excipient changes alone may not resolve.

Potential formulation-development avenues include:

• Increasing delivery consistency without increasing systemic exposure beyond the approved safety profile
• Improving skin contact over body contours
• Reducing drug crystallization during wear
• Enhancing flux through the stratum corneum
• Improving adhesion during perspiration and movement

The regulatory barrier is substantial. A higher-flux formulation could change exposure, safety, and efficacy. It would likely require comparative pharmacokinetic and clinical support rather than a simple CMC change.

What formulation patents and intellectual-property barriers affect Twirla?

Twirla’s intellectual-property protection can extend beyond the active ingredients. Levonorgestrel and ethinyl estradiol are established compounds, so commercial protection is more likely to depend on the delivery system, adhesive matrix, patch construction, manufacturing process, and approved use.

Likely protected technical features

The relevant patent categories include:

• Drug-in-adhesive transdermal matrices
• Specific polymer and excipient combinations
• Controlled delivery of levonorgestrel and ethinyl estradiol
• Patch dimensions and drug loading
• Layered patch construction
• Manufacturing and coating processes
• Stability and crystallization control
• Contraceptive methods using the approved patch

The Orange Book should be reviewed for current listed patents and regulatory exclusivity associated with NDA 210186. Patent term, pediatric extensions, terminal disclaimers, and the scope of any listed claims determine the practical timing of generic competition.[2]

Why excipient changes can strengthen or weaken exclusivity

An excipient formulation can create a defensible product profile when the claims cover a specific matrix composition or functional result. The strongest claims generally connect:

• A defined polymer system
• A specific active-ingredient loading
• A measurable release profile
• Seven-day delivery
• Adhesion or stability performance
• A manufacturing condition that produces the required matrix

Broad claims covering conventional pressure-sensitive adhesives are more vulnerable to prior-art challenges. Narrow claims tied to a reproducible product-performance profile may be more useful in litigation and licensing.

A reformulated product can also create new patent opportunities, but it may expose the sponsor to an obviousness challenge if the change is a routine optimization of known adhesive materials.

When does Twirla lose exclusivity?

Twirla’s regulatory and patent exclusivity must be analyzed separately.

FDA exclusivity

Twirla received approval under the standard NDA pathway rather than as a new chemical entity. Its regulatory exclusivity is therefore shorter than the five-year exclusivity generally available to a new chemical entity. FDA approval records and the Orange Book provide the controlling information for any applicable exclusivity period.[2,3]

Patent expiry and generic entry

Generic entry depends on the latest enforceable patent claims, not solely on the original approval date. A generic applicant may file an abbreviated new drug application with a Paragraph IV certification against listed patents before those patents expire. The sponsor may then bring patent litigation within 45 days, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[4]

For a transdermal product, generic entry is more complex than substitution of an oral tablet. The applicant must address:

• Active-ingredient equivalence
• Delivery rate
• Adhesion
• Peel and tack performance
• Residual drug
• Patch dimensions
• Matrix composition
• Stability
• Application-site performance

FDA product-specific guidance and any approved reference-product standards determine the required evidence.[5]

What Paragraph IV challenges and generic entry risks exist?

The principal generic risk is a patch that matches Twirla’s delivery profile while using a different adhesive or matrix system.

Generic development pathways

A competitor could pursue:

1. An ANDA using the same active ingredients and a comparable transdermal system.
2. A 505(b)(2) application if the product differs materially in formulation, patch construction, or delivery characteristics.
3. A licensed or authorized generic strategy if commercial rights become available.
4. A non-hormonal or progestin-only patch that competes for the same users without directly copying Twirla.

A transdermal generic may face more CMC and performance testing than a conventional tablet. The reference product’s adhesion and wear characteristics can become practical barriers even when the active ingredients are old.

Generic substitution risk

Pharmacy substitution may be less automatic than with a conventional oral contraceptive if state substitution rules, dosage-form differences, or FDA therapeutic-equivalence determinations limit interchangeability. A sponsor with strong device, adhesive, and process patents can use those rights to delay or narrow generic entry.

How does Twirla compare with Xulane?

Twirla and Xulane are both weekly combined hormonal contraceptive patches, but they use different progestins and have different delivery systems.

Attribute	Twirla	Xulane
Estrogen	Ethinyl estradiol	Ethinyl estradiol
Progestin	Levonorgestrel	Norelgestromin
Dosing	Weekly	Weekly
Delivery	Transdermal	Transdermal
Commercial position	Lower-estrogen patch positioning	Established generic and branded patch market
Key differentiation	Levonorgestrel formulation and patch design	Longer commercial history and broader market familiarity
Main formulation battleground	Adhesion, tolerability, matrix performance	Generic competition, adhesion, and exposure profile

Twirla’s commercial differentiation is its active-ingredient combination and lower nominal daily estrogen delivery compared with older norelgestromin/ethinyl estradiol patch products. Its challenge is that contraceptive users and prescribers can choose oral contraceptives, long-acting reversible contraceptives, vaginal rings, injections, implants, and competing patches.

What FDA regulatory opportunities exist for a Twirla reformulation?

The regulatory route depends on the scope of the change.

Changes likely to require an NDA supplement

A change in the adhesive polymer, drug-layer composition, patch size, drug loading, release liner, backing film, or manufacturing process may require a prior-approval supplement if it could affect product performance.

FDA review would likely focus on:

• Assay and content uniformity
• In vitro release
• Adhesion and wear
• Peel and tack
• Residual drug
• Impurities and degradation products
• Extractables and leachables
• Skin irritation and sensitization
• Pharmacokinetics
• Stability under ICH conditions

A formulation change that alters systemic exposure may require clinical bridging or additional efficacy and safety data.

Lower-risk CMC opportunities

The most practical near-term opportunities are changes that preserve the approved drug-in-adhesive system while improving manufacturing or supply reliability:

• Alternate qualified polymer suppliers
• Tighter particle-size specifications for crospovidone
• Improved solvent-removal controls
• More robust coating-window controls
• Reduced matrix crystallization
• Higher-throughput coating equipment
• Packaging improvements that reduce humidity exposure

These changes can lower cost of goods without creating a new clinical development program, although the regulatory filing category depends on the specific change.

Which companies could commercialize Twirla-related excipient technologies?

The most relevant partner categories are:

Pressure-sensitive adhesive suppliers

Specialty adhesive manufacturers can provide polyisobutylene grades, acrylic alternatives, silicone systems, tackifiers, and coating expertise. The commercial value lies in a validated formulation that improves wear while preserving drug delivery.

Transdermal manufacturing specialists

Contract development and manufacturing organizations can offer:

• Hot-melt coating
• Solvent coating
• Roll-to-roll lamination
• Die cutting
• Vision inspection
• In-line weight control
• Sachet and pouch packaging

A supplier with transdermal scale-up capability can reduce technical-transfer risk.

Excipient manufacturers

Crospovidone and polymer suppliers can support alternate-source qualification, particle engineering, moisture control, and regulatory documentation. A dual-source strategy can reduce supply risk for a product dependent on a narrow adhesive-matrix process window.

Packaging suppliers

High-barrier pouch systems can protect the patch from humidity, oxygen, and volatile-component loss. Packaging improvements may provide a faster commercial return than a new matrix chemistry if shelf-life, shipping, or storage failures are material issues.

How strong is the commercial opportunity for Twirla excipient innovation?

The opportunity is strongest in four areas.

Opportunity	Development difficulty	Commercial value
Improved adhesion during bathing and exercise	Moderate	High
Lower skin irritation and residue	Moderate	High
Lower manufacturing cost and improved yield	Low to moderate	High
Higher efficacy in users with BMI of 30 kg/m² or greater	High	Very high, but clinically and regulatorily complex

A successful excipient program could support:

• Premium pricing
• Improved prescription persistence
• Lower replacement rates
• Greater appeal to patients who dislike oral dosing
• Expansion into international markets
• Licensing to a contraceptive or transdermal-specialty company
• Follow-on products using the same patch platform

The largest strategic limitation is that the product’s commercial ceiling is determined by the broader contraceptive market and the FDA-labeled BMI limitation. Adhesive improvements can increase usability, but they do not automatically eliminate safety warnings or expand the approved population.

What manufacturing and intellectual-property barriers limit competitors?

Twirla’s technical barriers are concentrated in process control and product-performance replication.

Manufacturing barriers

Competitors must control:

• Drug dispersion in the adhesive
• Coating thickness
• Solvent removal
• Matrix crystallization
• Lamination pressure
• Die-cut dimensions
• Patch edge integrity
• Pouch seal quality
• Stability during shipment

Small process changes can alter release kinetics and adhesion. These requirements favor manufacturers with established transdermal operations.

IP barriers

Potential barriers include claims covering the patch architecture, adhesive matrix, active-ingredient combination, release characteristics, and manufacturing method. Method-of-use claims may also cover contraceptive administration schedules or patient populations.

The commercial strength of the estate depends on claim breadth, patent remaining life, prior-art exposure, Orange Book listing status, and whether a generic can design around the adhesive matrix without losing therapeutic equivalence.

What licensing deals could create value?

A Twirla-related licensing transaction could take several forms:

1. Regional rights for markets where transdermal contraception is underdeveloped.
2. Co-development of an improved-adhesion patch.
3. Supply and technology-transfer agreements for adhesive matrices.
4. Authorized-generic rights after patent expiry.
5. Platform licensing for other hormones or chronic drugs.
6. Manufacturing partnerships that reduce cost of goods.
7. Combination-product licensing involving smart adherence monitoring.

The most defensible transaction would link a formulation improvement to validated performance data, a defined regulatory pathway, and freedom-to-operate analysis. A generic excipient supply agreement alone would usually have less strategic value than a co-exclusive platform license with manufacturing know-how.

Key Takeaways

• Twirla uses a drug-in-adhesive transdermal system containing levonorgestrel and ethinyl estradiol.
• Polyisobutylene and crospovidone are disclosed functional excipients in the product formulation.
• The highest-value excipient opportunities are improved seven-day adhesion, lower skin irritation, reduced residue, and better performance under heat and moisture.
• CMC improvements that preserve drug delivery may offer the fastest route to commercial value.
• A higher-flux formulation for users with BMI of 30 kg/m² or greater would have substantial market value but would face significant clinical and regulatory requirements.
• Generic competition will depend on transdermal equivalence, adhesion performance, Orange Book patents, and Paragraph IV litigation.
• Twirla’s commercial differentiation from Xulane is based on its levonorgestrel formulation, patch design, and lower nominal daily estrogen delivery.
• Excipient suppliers, transdermal manufacturers, packaging companies, and specialty contraceptive licensors are the most relevant commercial partners.

FAQs

Can Twirla use a silicone adhesive instead of polyisobutylene?

A silicone adhesive could be technically feasible, but it would represent a substantial formulation change. The sponsor would need to demonstrate comparable drug delivery, adhesion, stability, irritation, sensitization, and manufacturing performance.

Can crospovidone be replaced with another matrix modifier?

Yes, but replacement would require comparability data. Particle size, moisture, grade, and supplier changes can affect drug dispersion, crystallization, release rate, and adhesive cohesion.

Is Twirla eligible for automatic generic substitution?

Automatic substitution depends on FDA therapeutic-equivalence determinations and applicable state pharmacy laws. A transdermal patch may face greater substitution complexity than an oral contraceptive because adhesive and delivery performance are product-defining characteristics.

Could an excipient change extend Twirla’s patent life?

An improved formulation may support new patent claims, but it would not automatically extend existing patent rights. Patentability would depend on novelty, non-obviousness, claim scope, and the relationship between the excipient change and demonstrated product performance.

What is the most attractive commercial reformulation for Twirla?

A formulation that improves seven-day adhesion while reducing residue and skin irritation is the most commercially practical opportunity. It addresses user experience, persistence, product replacement, and competitive differentiation without necessarily requiring the higher clinical risk of an increased-delivery formulation.

References

1. U.S. Food and Drug Administration. (2023). Twirla (levonorgestrel and ethinyl estradiol) transdermal system: Prescribing information. Agile Therapeutics, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2020). Twirla approval letter and application approval history, NDA 210186. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355.

5. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. FDA.

6. U.S. Food and Drug Administration. (2020). Transdermal and topical delivery systems: Product development and quality considerations. FDA.